Jeff Yass’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-499,801
| Closed | -$5.93M | – | 10878 |
|
|
2018
Q1 | $4.54M | Buy |
499,801
+481,852
| +2,685% | +$2.66M | ﹤0.01% | 2666 |
|
|
2017
Q4 | $77K | Sell |
17,949
-28,867
| -62% | -$138K | ﹤0.01% | 8791 |
|
|
2017
Q3 | $66K | Sell |
46,816
-86,590
| -65% | -$121K | ﹤0.01% | 8480 |
|
|
2017
Q2 | $200K | Buy |
133,406
+85,864
| +181% | +$184K | ﹤0.01% | 8293 |
|
|
2017
Q1 | $122K | Sell |
47,542
-68,515
| -59% | -$159K | ﹤0.01% | 8307 |
|
|
2016
Q4 | $296K | Buy |
116,057
+93,120
| +406% | +$267K | ﹤0.01% | 7998 |
|
|
2016
Q3 | $71K | Buy |
22,937
+6,226
| +37% | +$19.4K | ﹤0.01% | 8046 |
|
|
2016
Q2 | $54K | Sell |
16,711
-5,260
| -24% | -$19.3K | ﹤0.01% | 8222 |
|
|
2016
Q1 | $68K | Sell |
21,971
-5,560
| -20% | -$18.2K | ﹤0.01% | 8584 |
|
|
2015
Q4 | $110K | Sell |
27,531
-32,756
| -54% | -$151K | ﹤0.01% | 8837 |
|
|
2015
Q3 | $276K | Buy |
60,287
+35,558
| +144% | +$186K | ﹤0.01% | 8183 |
|
|
2015
Q2 | $128K | Sell |
24,729
-162,680
| -87% | -$976K | ﹤0.01% | 9572 |
|
|
2015
Q1 | $1.17M | Sell |
187,409
-159,581
| -46% | -$921K | ﹤0.01% | 5424 |
|
|
2014
Q4 | $2.18M | Buy |
346,990
+83,242
| +32% | +$507K | ﹤0.01% | 4303 |
|
|
2014
Q3 | $1.6M | Buy |
263,748
+210,040
| +391% | +$1.43M | ﹤0.01% | 5019 |
|
|
2014
Q2 | $353K | Sell |
53,708
-6,177
| -10% | -$69.6K | ﹤0.01% | 8105 |
|
|
2014
Q1 | $1.43M | Buy |
+59,885
| New | +$868K | ﹤0.01% | 4885 |
|
|
2013
Q4 | – | Sell |
-26,158
| Closed | -$289K | – | 9531 |
|
|
2013
Q3 | $349K | Buy |
26,158
+14,393
| +122% | +$228K | ﹤0.01% | 6990 |
|
|
2013
Q2 | $154K | Buy |
+11,765
| New | +$159K | ﹤0.01% | 7622 |
|
Other funds holding ECYT
Jeff Yass's ECYT Position: Q2 2018 in Review
Jeff Yass sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 499,801 shares — an estimated $5.93M sold.
Jeff Yass first reported a position in ECYT in Q2 2013 and held it in 19 quarters. The position peaked at $4.54M in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.
- Jeff Yass reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
- Jeff Yass sold 499,801 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $5.93M.
- Jeff Yass first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 19 quarters.
- Jeff Yass's Endocyte, Inc. Common Stock position peaked at $4.54M in Q1 2018.
- 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.
Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.